Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Homeobox protein SIX5 (SIX5) is a member of the sine oculis (SIX) family of transcription factors, sharing a conserved N-terminal SIX domain (protein-protein interactions) and a homeodomain (DNA binding). It is essential in vertebrate development, notably for the retina, spermatogenesis, and the cardiac conduction system, but not directly required for skeletal muscle phenotype in myotonic dystrophy type 1. Reduced SIX5 function, often stemming from DMPK locus trinucleotide expansion in myotonic dystrophy, contributes to multisystem manifestations such as cataracts and conduction defects. The SIX5 gene is subject to epigenetic regulation, and altered expression and methylation status play pathogenic roles in DM1. No approved drugs directly target SIX5, and its principal functions are as a sequence-specific DNA binding protein modulating transcription during development and tissue homeostasis.
Not applicable; no specific drugs or inhibitors targeting SIX5 are reported. Mechanism relates to transcriptional gene regulation via DNA binding and protein-protein interactions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Homeobox protein SIX5 (SIX5).